Quality of life in patients with advanced renal cell carcinoma in the randomized, open-label CheckMate 214 trial.

3073Background: In CheckMate 214, overall survival (OS) with nivolumab + ipilimumab (N+I) was superior to sunitinib (S; HR, 0.63; P<0.001) with a manageable safety profile as first-line treatment f...